Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Therapeutics signs deal with Duke University

This article was originally published in Scrip

Executive Summary

The Australian company Cancer Therapeutics has signed an agreement with Duke University in the US to discover and develop new drugs for the treatment of different forms of cancer. The agreement will be based on the work of Duke's Professor Patrick Casey, who has been investigating lipid signalling pathways and the role of lipid metabolising enzymes in cancer and has developed a series of new inhibitors for these. Cancer Therapeutics is to begin a drug development programme to bring these early-stage compounds towards the clinic.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC004888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel